- Home
- NDMO vs DNTH Comparison
NDMO vs DNTH Comparison
Compare NDMO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- DNTH
- Stock Information
- Founded
- NDMO 2019
- DNTH 2015
- Country
- NDMO United States
- DNTH United States
- Employees
- NDMO N/A
- DNTH N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- NDMO Finance
- DNTH Health Care
- Exchange
- NDMO Nasdaq
- DNTH Nasdaq
- Market Cap
- NDMO 621.8M
- DNTH 724.8M
- IPO Year
- NDMO N/A
- DNTH N/A
- Fundamental
- Price
- NDMO $10.50
- DNTH $23.67
- Analyst Decision
- NDMO
- DNTH Strong Buy
- Analyst Count
- NDMO 0
- DNTH 9
- Target Price
- NDMO N/A
- DNTH $46.43
- AVG Volume (30 Days)
- NDMO 218.6K
- DNTH 198.9K
- Earning Date
- NDMO 01-01-0001
- DNTH 03-20-2025
- Dividend Yield
- NDMO 6.75%
- DNTH N/A
- EPS Growth
- NDMO N/A
- DNTH N/A
- EPS
- NDMO N/A
- DNTH N/A
- Revenue
- NDMO N/A
- DNTH $5,366,000.00
- Revenue This Year
- NDMO N/A
- DNTH $100.14
- Revenue Next Year
- NDMO N/A
- DNTH N/A
- P/E Ratio
- NDMO N/A
- DNTH N/A
- Revenue Growth
- NDMO N/A
- DNTH 51.41
- 52 Week Low
- NDMO $8.99
- DNTH $18.35
- 52 Week High
- NDMO $11.24
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- NDMO 55.65
- DNTH 53.31
- Support Level
- NDMO $10.44
- DNTH $22.77
- Resistance Level
- NDMO $10.54
- DNTH $25.46
- Average True Range (ATR)
- NDMO 0.08
- DNTH 1.49
- MACD
- NDMO -0.01
- DNTH 0.13
- Stochastic Oscillator
- NDMO 44.20
- DNTH 57.18
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.